Change of Name

20 May 2011

Oxford Nutrascience Group plc

("Oxford Nutrascience" or "the Company")

Change of name to Oxford Pharmascience Group

Oxford Nutrascience the speciality pharmaceutical company that uses advanced pharmaceutic technologies to reposition medicines adding value to generic and soon to be off patent Active Pharmaceutical Ingredients (API's). announces that, following recent shareholder approval, the Company's name has changed to Oxford Pharmascience Group Plc. The Company will commence trading on the AIM Market of London Stock Exchange Plc under this new name and under the trading symbol "OXP" from Monday 23 May 2011. 

The new name reflects the Company's strategy which has evolved significantly during the last 12 months as it has expanded its technology base and expertise away from nutraceuticals to development and licensing of advanced medicines. The Company's technology portfolio includes superior chewable tablets, liquid suspensions and solid state suspensions (soft chews) as well as drug delivery technologies to achieve targeted release or taste masking effects. The Company is using these technologies to develop a range of medicines initially with focus on NSAIDs, statins and calcium focusing primarily on the pharmaceutical sector.

The Company's new website address will be www.oxfordpharmascience.com where further information on the Company can be found including information as required by AIM Rule 26.

- Ends -

For further information:

Oxford Pharmascience Group Plc

Nigel Theobald, Chief Executive +44 1865 854874

Mark Way, Investor and Media Relations +44 7786 116991

ZAI Corporate Finance (Nominated Adviser)

John Depasquale +44 20 7060 2220

Sarang Shah +44 20 7060 2220

About Oxford Pharmascience Group Plc

·; Oxford PharmaScience are specialists in the repositioning of medicines via reformulation using advanced pharmaceutic technologies to add value to generic and soon to be generic drugs;

·; Technology portfolio includes superior chewable tablets, liquid suspensions, and solid state suspensions (soft chews) as well as modified drug delivery technologies to achieve either taste masking or targeted release effects.

·; The company uses its technologies to develop Drug Master Files (DMF's) and full CTD dossiers (drug registration dossiers) for a range of medicines initially with focus on NSAIDs, statins and calcium.

·; Oxford Pharmascience works closely with leading academic institutions to further advance its intellectual property portfolio to apply to generic and soon to be generic drugs.